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Enterohemorrhagic Escherichia coli are important human food-borne pathogens. Recently, Shiga toxin-
producing E. coli (STEC) causes life-threatening hemolytic-uremic syndrome (HUS). In this study, Stx2B 
gene, a subunit of Shiga toxin, was amplified via polymerase chain reaction (PCR) from the 
chromosomal DNA of clinical fecal sample using appropriate primers. The PCR product was cloned to 
commercially available plasmid pH6HTN His6HaloTag® T7 containing two purification tags, namely, six 
histadine tag and Halo tag. The integrity of the constructed plasmid was confirmed using restriction 
enzyme mapping and sequencing. Then, Stx2B protein expressed after induction with isopropyl β-D-1-
thiogalactopyranoside (IPTG) in E. coli JM109 (DE3) under the control of the T7 promotor. The two step 
purification trains were used to purify native Stx2B. First step purification was Ni-immobilized metal ion 
affinity chromatography (IMAC) column, followed by second step using HaloLink resin. The native 
Stx2B was obtained after column cleavage of halo-tag using HaloTEV protease. Maximum protein 
expression of Stx2B economically was obtained using 1 mM IPTG for 4 h at 37°C. Protein identity was 
confirmed by a band at ~11.4 kDa using 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and StxB2 yield was 450 µg ml
-1
 confirmed by Bradford assay. Recombinant Stx2B protein 
was produced in highly pure yield using HaloTag technology.   
 





Enterohemorrhagic Escherichia coli (EHEC) strains are 
important human food-borne pathogens (Kaper et al., 
2004). The clinical manifestations of EHEC infections 
range from watery diarrhea or hemorrhagic colitis (HC), 
to the most severe outcome, the life-threatening 
hemolytic-uremic  syndrome  (HUS)  (Nataro  and  Kaper, 
1998). Currently, there are no specific protective measures 
or therapy against EHEC infection other than supportive 
therapy; as the utility of antibiotic or anti-diarrhetics 
treatment may be a risk factor for HUS and there is 
insufficient evidence to recommend antibiotic treatment 
for EHEC infection as reported by Nguyen and Sperandio  
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Although, the magnitude of the social and economic 
impacts caused by EHEC infections is high, no licensed 
vaccine or effective therapy is presently available for 
human use. So far, a number of experimental approaches 
are being investigated in animals. For example, Donohue-
Rolfe et al. (1989) reported that a monoclonal antibody 
against the Stx2B subunit recognizes and neutralizes 
both Stx1 and Stx2 in the HeLa cell cytotoxicity assay. 
The immune-prophylactic potential of the Stx1B subunit 
has been proven in the publication from different 
laboratory such as Boyd et al. (1991) and Acheson et al. 
(1996). In recent study, the immune-modulatory potential 
of recombinant Shiga toxin B subunit (rStxB) protein in 
BALB/c mice was evaluated. Animal protection with 
recombinant StxB was conferred through both humoral 
and cellular immune responses (Gu et al., 2011). 
Recently, the large scale production of stx2 in E. coli for 
toxoid vaccine antigen was achieved by Hideyuki et al. 
(2013).  
Several studies showed evidence that a closer 
association between Stx2 expression by Shiga toxin-
producing E. coli (STEC) and a more severe course of 
illness than Stx1 as were reported in both Scotland et al. 
(1987) and Hashimoto et al. (1999) studies. For example, 
in a recent outbreak involving 131 Japanese patients 
infected with Stx1-producing O118:H2 STEC serotype, 
no case of HUS was reported, and the gastrointestinal 
symptoms were relatively mild (Marcato et al., 2001). In 
addition, it has been proposed that a cellular vaccine 
consisting of a nontoxic Stx2B or combined with other 
proteins (Dubendorff and Studier, 1991) might provide 
safe and effective protection against the most severe 
complications of EHEC infections (Hanahan, 1983). This 
is better than the use of holotoxin Stxs as the expression 
of holotoxin may lead to instability of the expression 
strain or mutations accumulation due to the enzymatic 
activity of A subunits (Hopwood, 2003). Therefore, these 
epidemiological findings make Stx2B a compelling 
candidate for vaccine development in present study. 
In this research, an easy way was developed to build 
recombinant plasmid pH6HTN His6HaloTag® T7-Stx2B to 
get high yield of recombinant Stx2B (rStx2B) that could 




MATERIALS AND METHODS 
 
Bacterial strains, plasmid and media 
 
One clinical isolate of E. coli containing stx1AB and stx2AB genes was 
collected from Abu El-Reesh Hospital, Cairo University’s fecal 
samples. A clinical EHEC was tested for the inability to utilize 
sorbitol by plating on sorbitol MacConkey (SMA) agar (Oxoid, USA) 
at 37°C. Also, biochemical profile was performed by API 20E 
(BioMérieux, France) according to the manufacturer’s instructions. 
E. coli DH5α (Promega, USA) (Hanahan, 1983) and E. coli JM109 
(DE3) (Promega, USA) were used as hosts for cloning and protein 
expression, respectively.  




The prokaryotic plasmid pH6HTN His6HaloTag® T7 (4,014 kb, 
Promega, USA) was used for gene cloning and expression in E. 
coli. All E. coli strains were grown on Luria Bertani (LB) (Oxoid Ltd., 
Basingstok, Hampshire, England) liquid or agar medium at 37°C 




Construction of Stx2B expression plasmid 
 
DNA cloning and further manipulations were carried out according 
to methods described by Hopwood (2003) and Sambrook and 
Russell (2001). The DNA of clinical EHEC isolate was used as 
template for polymerase chain reaction (PCR) amplification of Shiga 
toxin 2B gene after purified by wizard genomic DNA purification kit 
(Promega, USA) according to manufacturer’s structures. PCR was 
performed in a programmable thermo-cycler PCR Machine 
(Touchgene Gradient, USA) using the specific primers (IDT DNA, 
USA): P1:5-cgTCTAGAATGAAGAAGATGTTTATGGCGGTT-3 and 
P2:5-ttGCGCCGCTCAGTCATTATTAAACTG-3. The forward 
pr imer  (P1) contained an engineered XbaI site (underlined) and 
the reverse primer (P2) incorporated an engineered NotI site 
(underlined). The amplification of stx2B by PCR was performed 
using Flexi GoTaq DNA polymerase (Promega, USA) and primer 
P1 and P2 under the following conditions: one cycle of denaturation 
(95°C for 10 min); 30 cycles of denaturation (95°C for 30 s), 
annealing (54°C for 30 s), extension (72°C for 45 s); followed by a 
final extension (72°C for 10 min).  
Both the purified amplicon of stx2B gene and his6halotag t7 
plasmid were double digested with FastDigest XbaI/NotI (Thermo-
Scientific, USA) according to the manufacturer's specifications. 
Ligation took place under optimal reaction conditions using T4-DNA 
ligase according to New England BioLabs (NEB) manufacturer’s 
protocol, with an insert: vector ratio of 3:1, respectively. The 
reaction was performed at 16°C for 18 min in thermo-cycler PCR 
machine at a final reaction volume of 20 μl containing 0.2 μg.μl-1 for 
digested PCR fragment, 1 μg.μl-1 for linearized vector, 2 μl for 10x 
ligation buffer and 1 μl for (1 unit) T4 ligase. The mixing was done 
gently by pipetting the solution up and down. 
The cloned vector was used to transform chemically prepared 
competent E. coli DH5α and was cultured on Luria Broth (LB) 
medium containing 100 µg.ml-1 of ampicillin. The resulted colonies 
were tested for further analysis for the presence of an insert into the 
multiple cloning sites (MCS) by using colony PCR primer for PCR 
amplification reaction that proceed part from MCS of pH6HTN 
His6HaloTag T7 vector using the specific primers  (IDT DNA, USA); P1 
(forward primer): 5-GGTCTGAATCTGCTGCAAGAA-3 and P2 (reverse primer): 5-
ACATGGCGATAGCTAGACTG-3. The thermal cycler protocol was 
performed according to the previous conditions except annealing 
temperature was 52.7°C for 30 s. The E. coli cells which carry 
empty vector were used as a negative control. 
The positive colonies were subjected to another colony PCR 
analysis for identifying the correct orientation (in frame) of the gene 
insert (stx2B) in the pH6HTN His6HaloTag vector. Moreover, the 
positive E. coli DHα5 colonies harboring correct recombinant vector 
of stx2B gene were subjected to XbaI/NotI double digestion 
restriction analysis to ensure insertion of the desired insert. 
The clone harbouring plasmid DNA from positive clone was 
isolated with QIAGEN® Plasmid Purification kit (Qiagen, Germany). 
The resulting purified plasmid pH6HTN His6HaloTag®T7–Stx2B 
was transformed into final host of chemically competent E. coli 
JM109 (DE3) and was cultured on LB medium containing 100 µg. ml-
1 of ampicillin. 
 
 
Stx2B expression and purification 
 
Expression of Stx2B  in  E.  coli  was  carried  out  as  described  by 




Studier et al. (1990). Expression was performed under the control 
of the T7 promotor using E. coli JM109 (DE3) strains. Single colony 
harbouring the plasmid His6HaloTag T7-Stx2B and His6HaloTag 
T7 (empty vector as negative control) were grown overnight in 3 ml 
LB medium containing 100 μg.ml-1 ampicillin at 37°C on a shaker 
incubator 250 rpm. 200 μl of these pre-cultures were used to 
inoculate 20 ml fresh LB medium in 250 ml normal flasks and let 
them grow at 37°C on shaker incubator 120 rpm to an OD600 nm of 
0.5 to 0.6.  
 
 
Optimization of the Stx2B expression 
 
Five flasks of previous cultures were induced by the addition of 
different concentration of isopropyl β-D-1-thiogalactopyranoside 
(IPTG; 0.1, 0.25, 0.5, and 1 mM) and one culture was un-induced. 
Induction was continued for different time periods (0 h, 4 h and 
overnight) at incubation temperature (37°C) with shaking at 120 
rpm. The above experiment was repeated at 30°C incubation 
temperature instead of 37°C. Then aliquots were removed at 
different time points for analysis. Induced cultures were transferred 
to falcon tube to harvest by centrifugation for 30 min at 13,000 rpm 
at 4°C and the pellets were washed twice with lysis buffer (ice cold 
50 mM Na2HPO4/MOPS, 300 mM NaCl, 5 mM Imidazole, and 0.25 
µg/µl (p-amidinophenyl)methanesulfonyl fluoride (APMSF), pH at 
7.0) then were kept in -20°C until used. 
 
 
Batch purification Stx2B protein from E. coli under native 
condition 
 
Purification of His6HaloTagged Stx2B proteins using IMAC by 
gravity-flow 
 
The pellets were re-suspended in lysis buffer in ratio 1:10. The 
extent of sonication was tightly controlled: sonication in 4 cycles 
(each at 20 s on at 35% power, 60 s off, at 0°C) (Elma, USA). The 
resulting cell lysate was centrifuge at 12,000 × g for 20 min at 4°C 
to remove the unlysed cells and insoluble proteins. The supernatant 
was collected and loaded onto a profanity nickel metal charged 
resin (Bio-Rad, Hercules CA, USA) Econo-Pac® column that had 
been pre-equilibrated with 5 column volumes (CVs) buffer A (50 
mM Na2HPO4/MOPS, 300 mM NaCl and 5 mM imidazole, pH at 
7.0).  
Then, the column was washed with 5 CVs of buffer A to remove 
unbound sample and the resulted fractures (0.5 ml/fraction) were 
pooled for further analysis. After that, the His6HaloTagged Stx2B 
protein was eluted with buffer A containing 500 mM imidazole and 
then protein containing fractions (0.5 ml/fraction) were pooled and 
analyzed using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  
 
 
Further purification of His6HaloTagged Stx2B proteins using 
halo-link resin  
 
The His6HaloTagged Stx2B protein resulted from previous 
purification was subjected to further purification by HaloLink resin 
(Promega, USA) by batch purification. About 2 ml (0.5 ml settled) 
HaloLink resin was equilibrated with 10 CVs of Halotag purification 
buffer (50 mM MOPS and 120 mM NaCl, pH at 7.0) by inverting the 
tube until thoroughly mixed. Then, resin was centrifugation at 1,000 
× g for 10 min at 4°C and washed twice with the same buffer 
followed by centrifugation. 1 ml of His6HaloTagged Stx2B IMAC 
purified protein previously purified was incubated with the Halolink 
resin at 4°C overnight with constant mixing, and collected by 
centrifugation at 1,000 × g for 10 min at 4°C. The resin was washed 





the tube, the resin centrifugation at 1,000 × g for 10 min at 4°C and 
the supernatant was discarded, and a total of two washed was 
performed. 
Afterwards, the resin was incubated with 0.55 ml cleavage 
solution (50 mM MOPS and 120 mM NaCl, pH at 7.0) containing 33 
µl of HaloTEV protease (Promega, USA) for 90 min at room 
temperature. The supernatant was separated by centrifugation at 
10,000 × g for 5 min and the resin was washed with Halotag 
purification buffer and both supernatants were combined. The 





Electrophoresis of proteins was performed using SDS-PAGE 
according to Laemmli (1970) where the final concentration of 
acrylamide in the stacking and separating gels was 4 and 15%, 
respectively.  
The gels were scanned with a Digital Camera (Cannon, Japan) 
and analyzed using the software package GelCompar II, 6.5 
(Applied Maths, Belgium). The pertained protein ladder” Broad 
Range (6.5-200 kDa) (Servea, USA) was used as internal reference 
of molecular weight for normalization. The concentration of resulted 
Stx2B protein was determined using the Bradford assay (Thermo 





Construction of Stx2B expression plasmid 
 
Genomic DNA from EHEC clinical isolate was used to 
isolate the gene coding for Stx2B. Thus, the 270 bp PCR 
ampilicon size carrying XbaI/NotI restriction sites on the 
5’ and 3’ flanking regions, respectively (Figure 1B; Lane 
1) was cloned into the pH6HTN His6HaloTag® T7 vector 
resulting in intermediate plasmid pH6HTN His6HaloTag® 
T7-Stx2B. 
The digestion of double restriction the pH6HTN 
His6HaloTag® T7 vector and Stx2 insert with Fast Digest 
XbaI/NotI restriction enzymes resulting in the linearization 
of vector producing a band size ~3974 bp (Figure 1A; 
Lane2), while the PCR product of stx2B gene was 
observed at ~270 bp, (Figure 1B; Lane 1).  
 
 
Screening for recombinant stx2B gene for 
confirmation of insert 
 
The recombinant construct containing stx2B gene 
obtained after ligation was used for E. coli DH5α cells 
transformation. Among the colonies appeared on the LB 
Agar/ampicillin (100 µg.mL
-1
), the positive clone was 
screened initially by colony PCR using the primers 
designed from MCS of vector. The 350 bp of PCR 
product size corresponded to negative clone, while the 
595 bp ampilicon size corresponded to positive clone 
(Figure 1B, Lanes 3 and 4, respectively). 
The positive clone was subjected to colony PCR 
screening for correct insert orientation resulting in 435 bp 
ampilicon size (Figure 1B; Lane 5). The 4.244 kb plasmid 
DNA   of   positive   clone   was   double    digested   after  






Figure 1. Gel-electrophoresis of the PCR amplification products for cloning, restriction digests, and screening for correct clone. M: 1 kb 
DNA Marker, Lane 1: plain super-coiled vector at 4.014 kb, Lane 2: linearized digested plasmid product at 3.974 kb by double digestion 
with XbaI/NotI for cloning, Lane 3: super-coiled positive plasmid at 4.244 kb, Lane 4: two DNA bands of stx2B at 0.27 kb and linearized 
digested plasmid at 3.974 kb after restriction analysis (A). M: 100 bp DNA Marker, Lane 1: stx2B gene with XbaI/NotI restriction sites at 
270 bp, Lane 2: digested stx2B gene at ~270 bp, Lane 3: Negative clone at 350 bp, Lane 4: positive clone at 594 bp, Lane 5: correct 




purification (Figure 1A; Lane 3) resulting in two fragments; 
one of larger size which correspond to linearized vector 
(3.974 kb) and another of smaller size, which 
corresponded stx2B gene (270 bp) (Figure 1A; Lane 4). 
 
 
Stx2B protein expression and purification 
 
The construct containing the target gene (stx2B) was 
used to transform JM109 (DE3) cell. The cell has been 
confirmed to be transformed in the gene (stx2B) in the 
correct orientation insertion. The transformed cells were 
grown to test the ability of the host cell containing 
construct to produce recombinant protein. 
As evidenced by on GelComparII6.5 software after 
normalization; the expression of His6 Halo tagged 
recombinant Stx2B protein increased gradually by the 
gradual increase in IPTG concentration (0.1, 0.2, 0.5 and 
1 mM), respectively (Figure 2). Moreover, 37°C induction 
temperatures showed higher His6 Halo tagged 
recombinant Stx2B protein expression (Figure 2B) than at 
30°C induction temperature (Figure 2A). Overnight 
induction showed higher expression of the His6 Halo 
tagged recombinant Stx2B protein when compared with 
the observed expression when induction was conducted 
for 4 h (Figure 2A and B). 
 
 
Batch purification Stx2B protein from E. coli JM109 
(DE3) under native condition 
 
Purification of Stx2B protein using IMAC 
 
His6    Halo    tagged    recombinant    Stx2B   protein  was 
obtained in a soluble form in a relatively high purity level 
with a band corresponding ~47.5 kDa, Lanes 5 to 9, 
when phosphate buffer was replaced by MOPS buffer 
through Profinity IMAC Ni-charged resin (Figure 3). 
 
 
Further purification of His6HaloTagged Stx2B 
proteins using halo-link resin 
 
The resulted ~47 kDa His6Halo Tagged recombinant 
Stx2B protein from previous purification was subjected to 
undergo further purification by HaloLink resin with 
HaloTEV protease treatment. The resulted protein band 
was observed at ~11.4 KDa, Lane 10 corresponded to 
highly pure Stx2B protein (Figure 3). The final 








Several vaccine strategies have been used with variable 
success in a number of animal models. The strategies 
have involved the use of recombinant virulence proteins 
such as Stx, intimin and E. coli secreted protein A (EspA) 
(Gu et al., 2009) or peptides (Wan et al., 2011) or fusion 
proteins of A and B subunits of Stx2 and Stx1 such as 
Stx2Am-Stx1B (Cai et al., 2011) or avirulent host cells of 
EHEC O157:H7 (Cai et al., 2010). The application of live 
attenuated bacteria such as Salmonella as a carrier for 
vaccine proteins against mucosal pathogens including 
EHEC has obvious advantages (Hideyuki et al., 2013). 
The choice of Stx2B in the present study as compelling 
candidate  for  vaccine development in present study was  
 






Figure 2. SDS-PAGE analysis of optimization His6Halo tagged recombinant Stx2B protein expression in Escherichia  coli 
JM 109(DE3) cells transformed with pH6HTN His6HaloTag® T7. M: protein molecular weight marker (6.5-200 kDa), 
Lane 1-4: culture growth under 0.1, 0.2, 0.5, 1 mM of IPTG in 30°C at overnight, Lane 5-8: culture growth under 0.1, 
0.2, 0.5, 1 mM of IPTG in 30°C at 4 h) (A). M: protein molecular weight marker (6.5-200 kDa), Lane 1-4: culture growth 
under (0.1, 0.2, 0.5 and 1 mM of IPTG in 37°C at 4 h, Lane 5-8: culture growth under (0.1, 0.2, 0.5 and 1mM of IPTG in 






Figure 3. An image of a Coomassie blue-stained SDS-PAGE gel of cell lysates of Escherichia  coli 
JM109(DE3) strain  carrying the recombinant Stx2B plasmid  that were either not induced with IPTG (-) 
in Lane 1 or induced with 1 mM IPTG for overnight  (+) in Lane 2. Lane 3 contained a sample of the 
column flow through FT, Lane 4 contained a sample of the column wash (W), while Lanes 5-9 contain 
samples of the fractions eluted from the Profinity IMAC Ni-charged resin which indicates the position of 
the main component eluted from the column with a band size of approximately 47.5 kDa of 6xHis-Halo 
tagged Stx2B protein. (M) Contained protein molecular weight marker (Serva, USA) and the sizes of the 
respective bands were indicated. Lane 10 contained pure Stx2B ~11.4 kDa elution after removal of 






consistent with what have been reported in recent studies 
such as Fujii et al. (2012) and Mejias et al. (1996). 
However, some other studies showed contrasts, such as 
Liu et al. (2009) and Tu et al. (2009), where they used 
truncated Stx2A1 and the holotoxin Stx2 in their 
candidate vaccine, respectively. 
In this study, different conditions for the induction of 
Shiga toxin expression were examined including tem-
perature, IPTG concentration and the induction period in 
order to obtain the maximum level of protein production. 
Thus, Stx2B expression showed higher level of 
expression when Stx2B was induced at 37°C compared 
with 30°C. Similar results were obtained by Shan et al. 
(2010) and Madanchi et al. (2011) who reported that 
StxB-pQE40-DHFR and CtxB-linker-StxB-pET-28a 
expression systems showed a higher expression rate at 
37°C. In contrast, Liu et al. (2009) and Tu et al. (2009) 
have reported that 30 and 16°C was considered optimal 
for Stx2 holotoxin pET32b and for truncated Stx2A1 pET-
22b expression systems, respectively. 
In the present study, the expression of Stx2B protein 
was gradually increased when the concentration of IPTG 
was gradually increased. The expression was optimal at 
1 mM IPTG concentration. In contrast, Shan et al. (2010) 
study has employed 0.3 mM final IPTG concentration for 
mature StxB induction. 
The overnight induction of Stx2B protein at 30°C 
expression, have resulted in higher yield compared to 
induction for 4 h also the overnight induction period at 
37°C expression have little increase in yield compared to 
4 h induction. The induction for 4 h at 37°C appeared 
more economically preferred compared to overnight 
induction, as it has more productivity as well as saved the 
energy that was consumed for shaking. These results 
were consistent with that of Shan et al. (2010), as they 
used 37°C for 3 h for induction of mature Stx protein. 
However, Liu et al. (2009) reported that 30°C for 14 h 
time of induction of truncated Stx2A1 was the optimal. 
Hence, the optimum condition to induce the expression of 
Stx2B in pH6HTN His6HaloTag vector is 4 h incubation 
period with 1 mM IPTG at 37°C.  
The  two tag system is one example of tandem affinity 
purification (TAP) methods which offers an effective and 
highly specific means to purify target protein, protein 
capture, quantification, and reduces contaminants 
significantly (Esposito and Chatterjee, 2006; Puig et al., 
2011). To the best of our knowledge, this is the first 
report of the expression of a Halo-His6 fusion of the 
Stx2B protein. Despite, there were reports of purification 
of Stx2B as a fusion protein with glutathione S-
transferase (GST) (Mukhopadhyay et al., 2013) or hexa-
histidine (Madanchi et al., 2011).  Block et al. (2009) has 
reported that protein purified using His6Tag have 
significantly lower purity, which might be attributed to that 
fact that endogenous proteins have high affinity to metal 
ions, which inevitably bind to the resin and co- purify with 
the fusion protein.  




Moreover, Ohana et al. (2009) have compared the Halo 
tag backbone protein for expression of 23 human 
proteins in E. coli relative to GST and His6Tag revealed 
that 74% of the proteins were produced in soluble and 
pure form when fused to HaloTag compared to 39 and 
22%, respectively, for the other tags.  
One of the obstacles of studying protein-protein 
interaction is the contamination of the target protein 
especially with no any prior knowledge. In the present 
study, the His6HaloTag protein purification was affinity 
purified using IMAC by use of phosphate buffer. The use 
of phosphate buffer resulted in unstable pure protein 
and/or contaminated protein. In this work therefore, the 
pellets were incubated on ice with APMSF protease 
inhibitor before sonication to limit proteolytic clipping of 
the protein of interest. Unfortunately such treatment did 
not result on successful protein purification and 
separation. The phosphate buffer produced unstable pure 
protein and/or contaminated protein or non-purified 
protein, as all protein appeared in the flow through during 
purification.  
In this work, an experimental purification technique was 
designed using MOPS buffer instead of phosphate buffer. 
Such procedures well separated Shiga toxin and higher 
protein yield was obtained. The superiority of MOPS 
buffer in purification and separation of Shiga toxin 
protein, could be explained by the fact that MOPS is a 
weaker metal ion ‘’stripping’’ buffer than phosphate when 
used in the imidazole gradient elution (Hutchens et al., 
2009). In contrast Hideyuki et al. (2013) used phosphate 
buffer in TALON resin for purification Stx2 holotoxin. The 
discrepancy between the results might be attributed to 
the use of different experimental design than that used in 
this study. 
To improve the purity and yield of the target protein, 
further purification step by Halo tag technology coupled 
with proteolytic tag removal (Ohana et al., 2009) was 
performed. The final concentration of free tagged Stx2B 
reached to 450 µg/ml by using Bradford assay. This result 
was approximately two times higher compared to Halo 
tag-based purification of PKCƔ Kinase free tag protein 
(Ohana et al., 2011) which produced 244 µg/ml. In the 
present study, the final concentration of free tagged 
Stx2B protein suggested the  large scale production of 
Shiga toxin by the method used in this work could by 





To the best of our knowledge, this study represents the 
first example of cloning, expression and purification of a 
Stx2B protein using HaloTag technology in highly pure 
form.  Cloning of the Stx2B was successful in a new 
technology vector ‘’His6 Halo dual tags’’ and led to 
expression of soluble protein. Interestingly, due to 
problems that arose in all the steps  of  purification  stage 




using phosphate buffer for production contaminated 
unstable Stx2B protein resulted. This has been 
overcomed and improved by using the MOPS buffer 
rather than phosphate buffer in all steps of purification 
stage. 
According to the results, Stx2B protein yields obtained 
in the small scale experiments described in the present 
study were encouraging. Determination of the immuno-
genicity or the sensitivity, stability, specificity, accuracy 
and linearity of the purified Stx2B is still required to prove 
the usefulness of the application of this product in both 
developing and developed countries against Shiga toxin 
type 2B enterohemorrhagic E. coli in future prospective. 
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